teaser
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Sweden’s Medivir has been told that partner Bristol-Myers Squibb has terminated development of the firms’ preclinical HIV compound MIV-170.
The decision was taken “because the compound did not meet the profile desired” by the New York-based drugs major. The Swedish firm noted that MIV-170 belongs to a group
